CoChat
Sign Up
Cited by 590

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

BAP1 and cancer

Carbone, Michele, Yang, Haining, Pass, Harvey I., Krausz, Thomas, Testa, Joseph R., Gaudino, Giovanni·2013·Nature Reviews Cancer
DOI 10.1038/nrc3459PMC PMC3792854
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc3459

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. Carbone, M. et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nature Rev. Cancer 7, 147–154 (2007). · DOI
  2. Carbone, M. et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc. Natl Acad. Sci. USA 108, 13618–13623 (2011). · DOI · Paper page
  3. Roushdy-Hammady, I., Siegel, J., Emri, S., Testa, J. R. & Carbone, M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357, 444–445 (2001). · DOI
  4. Dogan, A. U. et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 66, 5063–5068 (2006). · DOI
  5. Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genet. 43, 1022–1025 (2011). · DOI · Paper page
  6. Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410–1413 (2010). · DOI
  7. Lu, Y. Y., Jhanwar, S. C., Cheng, J. Q. & Testa, J. R. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer 9, 76–80 (1994). · DOI
  8. Zeiger, M. A., Gnarra, J. R., Zbar, B., Linehan, W. M. & Pass, H. I. Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer 11, 15–20 (1994). · DOI
  9. Wiesner, T. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genet. 43, 1018–1021 (2011). · DOI
  10. Wiesner, T. et al. A distinct subset of atypical spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am. J. Surg. Pathol. 36, 818–830 (2012). · DOI
  11. Carbone, M. et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med. 1066, 179 (2012). · DOI
  12. Njauw, C. N. et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS ONE 766, e35295 (2012). · DOI
  13. Wiesner, T. et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J. Clin. Oncol. 30, e337–e340 (2012). · DOI
  14. Cagianut, B. Melanoma of the choroid and ciliary body, malignant meningioma and mesothelioma of the pleura (triple-malignoma) in a 63-year old female. Klin. Monbl. Augenheilkd. 161, 407–411 (1972).
  15. Abdel-Rahman, M. H. et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856–859 (2011). · DOI
  16. Aoude, L. G., Vajdic, C. M., Kricker, A., Armstrong, B. & Hayward, N. K. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res. 11 Dec 2012 (doi:10.1111/pcmr.12046). · DOI
  17. Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nature Genet. 44, 751–759 (2012). · DOI
  18. Wadt, K. et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res. 25, 815–818 (2012). · DOI
  19. Begg, C. B. et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J. Natl Cancer Inst. 97, 1507–1515 (2005). · DOI
  20. Li, F. P. & Fraumeni, J. F. Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747–752 (1969). · DOI
  21. Bheda, A., Shackelford, J. & Pagano, J. S. Expression and functional studies of ubiquitin C-terminal hydrolase L1 regulated genes. PLoS ONE 466, e6764 (2009). · DOI
  22. Fang, Y., Fu, D. & Shen, X. Z. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim. Biophys. Acta 1806, 1–6 (2010).
  23. Jensen, D. E. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097–1112 (1998). · DOI
  24. Mallery, D. L., Vandenberg, C. J. & Hiom, K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J. 21, 6755–6762 (2002). · DOI
  25. Nishikawa, H. et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 69, 111–119 (2009). · DOI
  26. Ventii, K. H. et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 68, 6953–6962 (2008). · DOI
  27. Misaghi, S. et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol. Cell. Biol. 29, 2181–2192 (2009). · DOI
  28. Tyagi, S., Chabes, A. L., Wysocka, J. & Herr, W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol. Cell 27, 107–119 (2007). · DOI
  29. Eletr, Z. M. & Wilkinson, K. D. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem. Biophys. 60, 3–11 (2011). · DOI
  30. Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243–247 (2010). · DOI
  31. Simon, J. A. & Kingston, R. E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nature Rev. Mol. Cell Biol. 10, 697–708 (2009). · DOI
  32. Gutierrez, L. et al. The role of the histone H2A ubiquitinase Sce in Polycomb repression. Development 139, 117–127 (2012). · DOI
  33. Zhu, Q. et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 477, 179–184 (2011). · DOI
  34. Kemp, C. D. et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin. Cancer Res. 18, 77–90 (2012). · DOI
  35. Yu, H. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol. Cell. Biol. 30, 5071–5085 (2010). · DOI
  36. Gambetta, M. C., Oktaba, K. & Muller, J. Essential role of the glycosyltransferase sxc/Ogt in polycomb repression. Science 325, 93–96 (2009). · DOI · Paper page
  37. Dey, A. et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337, 1541–1546 (2012). · DOI
  38. Ruan, H. B. et al. O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1α stability. Cell Metab. 16, 226–237 (2012). · DOI · Paper page
  39. Yoshikawa, Y. et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 103, 868–874 (2012). · DOI
  40. Jube, S. et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 72, 3290–3301 (2012). · DOI
  41. Celona, B. et al. Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol. 966, e1001086 (2011). · DOI
  42. Horn, E. P., Hartge, P., Shields, J. A. & Tucker, M. A. Sunlight and risk of uveal melanoma. J. Natl Cancer Inst. 86, 1476–1478 (1994). · DOI
  43. Stokes, M. P. et al. Profiling of UV-induced ATM/ATR signaling pathways. Proc. Natl Acad. Sci. USA 104, 19855–19860 (2007). · DOI
  44. Landreville, S. et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin. Cancer Res. 18, 408–416 (2012). · DOI
  45. Flores, R. M. et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J. Thorac. Cardiovasc. Surg. 135, 620–626.e3 (2008). · DOI

Cited by

Sorted by citations

See all 590

Metadata

Authors
Carbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R., & Gaudino, G.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2013-02-14
Volume
13
Issue
3
Pages
153-159
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc3459
PMC
PMC3792854
Cited by
590
References
4
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review